220
Views
8
CrossRef citations to date
0
Altmetric
Inflammatory Bowel Disease

Perceptions of medication safety among patients with inflammatory bowel disease

, , , &
Pages 1076-1083 | Received 28 Jan 2010, Accepted 28 Apr 2010, Published online: 12 May 2010

References

  • Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Chen DM, Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 2006;4:621–30.
  • Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359:1541–9.
  • Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462–76.
  • D'Haens G, Baert F, van Assche G, Caenepeel P, Vergauwe P, Tuynman H, Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008;371:660–7.
  • Markowitz J, Grancher K, Kohn N, Lesser M, Daum F. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 2000;119:895–902.
  • Punati J, Markowitz J, Lerer T, Hyams J, Kugathasan S, Griffiths A, Effect of early immunomodulator use in moderate to severe pediatric Crohn disease. Inflamm Bowel Dis 2008;14:949–54.
  • Siegel CA, Levy LC, Mackenzie TA, Sands BE. Patient perceptions of the risks and benefits of infliximab for the treatment of inflammatory bowel disease. Inflamm Bowel Dis 2008;14:1–6.
  • Baars JE, Siegel CA, Kuipers EJ, van der Woude CJ. Patient's perspectives important for early anti-tumor necrosis factor treatment in inflammatory bowel disease. Digestion 2009;79:30–5.
  • Harvey RF, Bradshaw JM. A simple index of Crohn's-disease activity. Lancet 1980;1:514.
  • Johnson FR, Ozdemir S, Mansfield C, Hass S, Miller DW, Siegel CA, Crohn's disease patients' risk-benefit preferences: serious adverse event risks versus treatment efficacy. Gastroenterology 2007;133:769–79.
  • Cullen G, O'Toole A, Keegan D, Sheahan K, Hyland JM, O'Donoghue DP. Long-term clinical results of ileocecal resection for Crohn's disease. Inflamm Bowel Dis 2007;13:1369–73.
  • Man-Son-Hing M, Laupacis A, O'Connor AM, Biggs J, Drake E, Yetisir E, A patient decision aid regarding antithrombotic therapy for stroke prevention in atrial fibrillation: a randomized controlled trial. JAMA 1999;282:737–43.
  • Brundage MD, Feldman-Stewart D, Cosby R, Gregg R, Dixon P, Youssef Y, Phase I study of a decision aid for patients with locally advanced non-small-cell lung cancer. J Clin Oncol 2001;19:1326–35.
  • Adam JA, Khaw FM, Thomson RG, Gregg PJ, Llewellyn-Thomas HA. Patient decision aids in joint replacement surgery: a literature review and an opinion survey of consultant orthopaedic surgeons. Ann R Coll Surg Engl 2008;90:198–207.
  • Spiegel BM, Ho W, Esrailian E, Targan S, Higgins PD, Siegel CA, Controversies in ulcerative colitis: a survey comparing decision making of experts versus community gastroenterologists. Clin Gastroenterol Hepatol 2009;7:168–74, 174.e1.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.